X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SHASUN PHARMA NATCO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 13.2 123.9 10.7% View Chart
P/BV x 3.8 8.5 44.3% View Chart
Dividend Yield % 1.2 0.2 505.1%  

Financials

 NATCO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
SHASUN PHARMA
Mar-14
NATCO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,08094 1,146.5%   
Low Rs67146 1,472.1%   
Sales per share (Unadj.) Rs592.1214.2 276.4%  
Earnings per share (Unadj.) Rs188.45.3 3,530.8%  
Cash flow per share (Unadj.) Rs206.315.8 1,304.3%  
Dividends per share (Unadj.) Rs8.251.00 825.0%  
Dividend yield (eoy) %0.91.4 65.9%  
Book value per share (Unadj.) Rs833.653.3 1,562.8%  
Shares outstanding (eoy) m36.9056.62 65.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.50.3 453.2%   
Avg P/E ratio x4.613.1 35.5%  
P/CF ratio (eoy) x4.24.4 96.0%  
Price / Book Value ratio x1.11.3 80.2%  
Dividend payout %4.418.7 23.4%   
Avg Mkt Cap Rs m32,3113,958 816.4%   
No. of employees `0004.8NA-   
Total wages/salary Rs m3,2562,164 150.5%   
Avg. sales/employee Rs Th4,522.5NM-  
Avg. wages/employee Rs Th674.0NM-  
Avg. net profit/employee Rs Th1,439.0NM-  
INCOME DATA
Net Sales Rs m21,84812,127 180.2%  
Other income Rs m404229 176.1%   
Total revenues Rs m22,25212,356 180.1%   
Gross profit Rs m9,2841,009 920.1%  
Depreciation Rs m662594 111.5%   
Interest Rs m154415 37.1%   
Profit before tax Rs m8,872230 3,862.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920-73 -2,640.3%   
Profit after tax Rs m6,952302 2,301.1%  
Gross profit margin %42.58.3 510.7%  
Effective tax rate %21.6-31.7 -68.4%   
Net profit margin %31.82.5 1,277.2%  
BALANCE SHEET DATA
Current assets Rs m21,3076,884 309.5%   
Current liabilities Rs m5,9208,456 70.0%   
Net working cap to sales %70.4-13.0 -543.4%  
Current ratio x3.60.8 442.1%  
Inventory Days Days7362 118.9%  
Debtors Days Days107108 99.0%  
Net fixed assets Rs m14,9864,970 301.5%   
Share capital Rs m369113 325.7%   
"Free" reserves Rs m30,3532,875 1,055.8%   
Net worth Rs m30,7603,020 1,018.5%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m37,15113,347 278.3%  
Interest coverage x58.61.6 3,773.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.9 64.7%   
Return on assets %19.15.4 355.9%  
Return on equity %22.610.0 225.9%  
Return on capital %29.313.3 220.3%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m10,3225,843 176.7%   
Fx outflow Rs m2,9782,173 137.1%   
Net fx Rs m7,3433,669 200.1%   
CASH FLOW
From Operations Rs m4,636398 1,166.0%  
From Investments Rs m-11,155-1,635 682.3%  
From Financial Activity Rs m6,5091,309 497.4%  
Net Cashflow Rs m-1871 -25.3%  

Share Holding

Indian Promoters % 52.0 39.2 132.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.6 217.8%  
FIIs % 16.6 17.6 94.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 39.6 65.7%  
Shareholders   25,395 20,750 122.4%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  SUVEN LIFE  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ALEMBIC LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS